Clinical trials: Stage I Breast Cancer
Solid Tumors, Breast Cancer
A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer
This is a phase I/II clinical research study with BGT226, an inhibitor of phosphatidylinositol 3'-kinase (PI3K). The study consists of a Phase I dose escalation part followed by a safety expansion part and a Phase II expansion…
- Conditions
- Solid Tumors, Breast Cancer, Cowden Syndrome
- Trial name
- NCT00600275
- Testing
- BGT226
- Where
- 6 sites in United States, Canada and 1 more
- Volunteers
- 57 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Gastroesophageal Adenocarcinoma, Advanced Breast Cancer
A Study of [68Ga]Ga-DWJ155 in Adult Patients With Solid Tumors
The purpose of this study is to evaluate the imaging characteristics, safety, biodistribution and pharmacokinetics (PK) of [68Ga]Ga-DWJ155, also known as FKL480, in patients ≥ 18 years of age with advanced gastroesophageal…
- Conditions
- Advanced Gastroesophageal Adenocarcinoma, Advanced Breast Cancer, Triple-negative Breast Cancer, Advanced Non-small Cell Lung Cancer
- Trial name
- NCT07801508
- Testing
- [68Ga]Ga-DWJ155
- Where
- 2 sites in Australia, Japan
- Volunteers
- 66 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Vaccine Treatment for Advanced Breast Cancer
This 2-phase study will determine the safety of treating patients with breast cancer with the genetically engineered HyperAcute-Breast cancer vaccine.
- Trial name
- NCT00090480
- Testing
- HyperAcute - Breast cancer vaccine
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- NewLink Genetics Corporation
Advanced or Metastatic Solid Tumors
Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
This is a first-in-human, open-label, multicenter, Phase 1 study to evaluate the safety, tolerability and preliminary efficacy of IPH4502 and to determine the recommended Phase 2 dose (RP2D) in advanced solid tumors that are…
- Trial name
- NCT06781983
- Testing
- IPH4502
- Where
- 7 sites in United States, France
- Volunteers
- 145 people
- Sponsor
- Innate Pharma
Breast Cancer
Blood Sample Collection and Health Information Collection From Patients With Invasive Breast Cancer and Their Brothers and Sisters
RATIONALE: Collecting blood samples and health information from patients with invasive breast cancer and from their brothers and sisters over time may help the study of cancer in the future.
- Trial name
- NCT00445562
- Testing
- biologic sample preservation procedure, informational intervention
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- GenBasix Incorporated
Advanced Breast Cancer
A Phase I Study of TQB3616 on Tolerance and Pharmacokinetics
TQB3616 may work in cancer by stopping cancer cells from multiplying.TQB3616 is in a new class of drugs called CDK inhibitors.This research study is the first time that TQB3616 will be given to people.TQB3616 is taken by mouth…
- Trial name
- NCT03850873
- Testing
- TQB3616
- Where
- 4 sites in China
- Volunteers
- 40 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Solid Tumor, Metastatic Solid Tumor
Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)
This interventional study will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ART6043 as monotherapy or in combination with olaparib.
- Trial name
- NCT05898399
- Testing
- ART6043, Olaparib
- Where
- 27 sites in United States, Spain and 1 more
- Volunteers
- 181 people
- Sponsor
- Artios Pharma Ltd
Breast Cancer
A Study of GDC-0927 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
This is an open-label, dose-finding, safety, pharmacokinetics (PK), and evidence-of-activity study of GDC-0927 in postmenopausal women with locally advanced or metastatic Estrogen Receptor Positive (ER+) Human Epidermal Growth…
- Trial name
- NCT02316509
- Testing
- GDC-0927
- Where
- 13 sites in United States, Spain
- Volunteers
- 43 people
- Sponsor
- Genentech, Inc.
Metastatic Breast Cancer
ABI-008 Trial in Patients With Metastatic Breast Cancer
To determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) of ABI-008 giver every 3 weeks; to characterize the toxicities of ABI-008; and to determine the pharmacokinetic parameters for ABI-008 when given…
- Trial name
- NCT00531271
- Testing
- ABI-008 (nab-docetaxel)
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- Celgene
Breast Cancer, Solid Tumor
A Study of GNC-077 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
This study is an open-label, multicenter, dose-escalation and cohort expansion phase I clinical study to evaluate the safety, tolerability, pharmacokinetics characteristics or preliminary efficacy and antitumor activity in…
- Trial name
- NCT06609187
- Testing
- GNC-077
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Metastatic Breast Cancer
Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer
This is an open-label, three-part, multiple-dose study to evaluate safety, tolerability, and efficacy of U3-1402 in patients with HER3-positive metastatic breast cancer.
- Trial name
- NCT02980341
- Testing
- Patritumab Deruxtecan
- Where
- 26 sites in United States, Japan
- Volunteers
- 182 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Advanced Breast Cancer, Other Solid Tumors
A Notch Signalling Pathway Inhibitor for Patients With Advanced Breast Cancer (0752-014)
An investigational study to determine the safety/tolerability, and efficacy of a notch signaling pathway inhibitor in patients with metastatic or locally advanced breast cancer and other advanced solid tumors.
- Trial name
- NCT00106145
- Testing
- Comparator: MK0752, Notch Inhibitor, Comparator: MK0752, Notch Inhibitor - 450 mg, Comparator: MK0752, Notch Inhibitor - 3 days on, 4 off
- Volunteers
- 103 people
- Sponsor
- Merck Sharp & Dohme LLC
Metastatic Breast Cancer, Locally Advanced Breast Cancer
A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.
A Phase I/II, Open-label study to assess the safety, tolerability, pharmacokinetic, and antitumor efficacy of FWD1802 monotherapy in patients with ER+/HER2- unresectable locally advanced or metastatic breast cancer.
- Conditions
- Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer Stage IV, ER+/HER2- Breast Cancer
- Trial name
- NCT06064812
- Testing
- FWD1802
- Where
- 22 sites in China
- Volunteers
- 99 people
- Sponsor
- Forward Pharmaceuticals Co., Ltd.
Triple-Negative Breast Cancer, High-grade Serous Ovarian Cancer
Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors
This is a Phase I, open-label, multi-center trial designed to evaluate the safety, tolerability and pharmacokinetics of CUDC-907 administered orally to subjects with advanced/relapsed solid tumors.
- Conditions
- Triple-Negative Breast Cancer, High-grade Serous Ovarian Cancer, Solid Tumors, NUT Midline Carcinoma
- Trial name
- NCT02307240
- Testing
- CUDC-907
- Where
- 4 sites in United States
- Volunteers
- 43 people
- Sponsor
- Curis, Inc.
Breast Cancer, Brain Cancer
Study of Insulin-like Growth Factor (IGF)-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R
This phase I dose escalation study will evaluate IGF-Methotrexate conjugate (765IGF-MTX) in patients with advanced, previously treated tumors.
- Conditions
- Breast Cancer, Brain Cancer, Gastrointestinal Cancers, Genitourinary Cancers
- Trial name
- NCT02045368
- Testing
- IGF-Methotrexate conjugate
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- IGF Oncology, LLC
Progressive Metastatic Malignancies
Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies
This is a Phase 1, open-labeled, non-randomized, multi-center, competitive enrollment and dose-escalation study of ALT-801, the study drug.
- Trial name
- NCT00496860
- Testing
- ALT-801
- Where
- 4 sites in United States
- Volunteers
- 26 people
- Sponsor
- Altor BioScience
Breastcancer, Breast Neoplasm
SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer
This is a single arm, open label study of SV-BR-1-GM, a targeted immunotherapy for breast cancer. Eligible patients will have histological confirmation of breast cancer with recurrent and/or metastatic lesions.
- Trial name
- NCT03066947
- Testing
- SV-BR-1-GM, Cyclophosphamide, Interferon-alpha-2b
- Where
- 5 sites in United States
- Volunteers
- 24 people
- Sponsor
- BriaCell Therapeutics Corporation
Breast Neoplasms, Malignant Neoplasm of Breast
Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer
This is a Phase I/II, open-label dose-escalation study designed to evaluate the maximum tolerated dose (MTD) and dose-limiting side effects of ibrutinib (560 or 840 or 420 mg daily oral dose), given in combination with…
- Trial name
- NCT03379428
- Testing
- Trastuzumab, Ibrutinib 560 mg, Ibrutinib 840 mg
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- US Oncology Research
Advanced Breast Cancer, Advanced Lung Cancer
TIL Therapy for Patients With Advanced Solid Tumors
This study is a phase I clinical trial to investigate the safety and tolerability of NEOG-100 in patients with advanced breast cancer and lung cancer.
- Trial name
- NCT06107894
- Testing
- Tumor-infiltrating lymphocytes, IL-2
- Volunteers
- 12 people
- Sponsor
- NeogenTC
Breast Cancer Metastatic, Renal Cell Carcinoma (RCC)
Sapu003 in Advanced mTOR-sensitive Solid Tumors
This is a phase 1b, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics of Sapu003 in combination with Exemestane in in patients with advanced mTOR-sensitive solid tumors (HR+/HER2-negative…
- Conditions
- Breast Cancer Metastatic, Renal Cell Carcinoma (RCC), Neuroendocrine Tumors, Tuberous Sclerosis Complex (TSC)
- Trial name
- NCT07369505
- Testing
- Sapu003, Exemestane 25 MG
- Where
- Australia
- Volunteers
- 27 people
- Sponsor
- SAPU NANO (US) LLC